The presence of ADAMTSL5 antigen in primary melanoma, as well as in cutaneous and lymph node metastasis (data not shown) suggest that ADAMTSL5-specific T-cell responses can be driven in melanoma patients, with the possibility of induction of immune responses triggering/exacerbating psoriasis in permissive conditions (anti-PD-1 treatment). Here, ADAMTSL5 is linked to psoriasis.